PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34897655-1	2022	Fluoropyrimidines are chemotherapy drugs that may cause severe adverse events, and their metabolism occurs by dihydropyrimidine deydrogenase (DPD), coded by DPYD.	dihydropyrimidine	110-127	dihydropyrimidine dehydrogenase	Homo sapiens	142-145	
33105068-1	2021	BACKGROUND: To delineate the pharmacologically relevant dihydropyrimidine dehydrogenase (DPYD) variants in the Indian population.	dihydropyrimidine	56-73	dihydropyrimidine dehydrogenase	Homo sapiens	89-93	
15450176-1	2004	Dihydropyrimidine dehydrogenase (DPD) is the first and rate-limiting enzyme in the pathway for degradation of pyrimidines, responsible for the reduction of the 5,6-double bond to give the dihydropyrimidine using NADPH as the reductant.	dihydropyrimidine	188-205	dihydropyrimidine dehydrogenase	Homo sapiens	0-31	
15450176-1	2004	Dihydropyrimidine dehydrogenase (DPD) is the first and rate-limiting enzyme in the pathway for degradation of pyrimidines, responsible for the reduction of the 5,6-double bond to give the dihydropyrimidine using NADPH as the reductant.	dihydropyrimidine	188-205	dihydropyrimidine dehydrogenase	Homo sapiens	33-36	
34916829-2	2021	Deficiency of the critical metabolic enzyme dihydropyrimidine dehydrogenase (DPD) leads to excessive toxicity on exposure to fluoropyrimidine chemotherapy.	dihydropyrimidine	44-61	dihydropyrimidine dehydrogenase	Homo sapiens	77-80	
32516529-3	2020	Analysis of the DPD reaction(s) equilibrium position under anaerobic conditions revealed a reaction that favors dihydropyrimidine formation.	dihydropyrimidine	112-129	dihydropyrimidine dehydrogenase	Homo sapiens	16-19	
30628914-1	2019	OBJECTIVE: Certain polymorphisms of the DPYD gene encoding for the dihydropyrimidine dehydrogenase (DPD) enzyme are associated with fluoropyrimidine-induced toxicity.	dihydropyrimidine	67-84	dihydropyrimidine dehydrogenase	Homo sapiens	40-44	
21344302-1	2011	PURPOSE: Eniluracil (EU) is a potent dihydropyrimidine (DPD) inhibitor, which improves the oral bio-availability of 5-fluorouracil (5-FU) and may overcome fluoropyrimidine (FP) resistance in hepatocellular carcinoma (HCC).	dihydropyrimidine	37-54	dihydropyrimidine dehydrogenase	Homo sapiens	56-59	
34897655-1	2022	Fluoropyrimidines are chemotherapy drugs that may cause severe adverse events, and their metabolism occurs by dihydropyrimidine deydrogenase (DPD), coded by DPYD.	dihydropyrimidine	110-127	dihydropyrimidine dehydrogenase	Homo sapiens	157-161	
34797200-0	2021	Potential added value of combined DPYD/DPD genotyping and phenotyping to prevent severe toxicity in patients with a DPYD variant and decreased dihydropyrimidine dehydrogenase enzyme activity.	dihydropyrimidine	143-160	dihydropyrimidine dehydrogenase	Homo sapiens	34-38	
34797200-0	2021	Potential added value of combined DPYD/DPD genotyping and phenotyping to prevent severe toxicity in patients with a DPYD variant and decreased dihydropyrimidine dehydrogenase enzyme activity.	dihydropyrimidine	143-160	dihydropyrimidine dehydrogenase	Homo sapiens	39-42	
34506675-12	2021	IMPLICATIONS FOR PRACTICE: The syndrome of dihydropyrimidine deaminase (DPD) deficiency is an uncommon but well-described cause of severe toxicity related to fluoropyrimidine chemotherapy agents (5-fluorouracil and capecitabine).	dihydropyrimidine	43-60	dihydropyrimidine dehydrogenase	Homo sapiens	72-75